Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Website: www.atossatherapeutics.com

Address:

448 NW Market Street, Suite 500, Seattle, United States

Bunster Sep. 20 at 1:51 AM

$ATOS WEEK IN REVIEW SEPTEMBER 18 2026 PPS 16 PENNIES PRE RS.. whats weird is nothing about quays job in weeks and weeks since politico.Dickie still reads the mb and changed from his im here for ispy bullish to reality of the company. Cb will post soon. EVANGELINE MOST LKELY NOT TILL 2027.THE DISASTER THAT IT WAS AND ANYONE WHO THINKS IT WAS NOT A DISASTER IS IN DISNEYLAND AND IN DENIAL. PRIME I WILL BE THE FIRST TO TELL U THE NEXT PPS BIG DROP WILL COME IF THEY RAISE MORE MONEY SOON. TICKTOCK TICK TOCK GIRLS. ARE U READING THIS DICKIE????ASSUMING NO BIG PRICE MOVEMNET IF QUAY GETS JOB.

0 · Reply

Warrens__Buffet_ Sep. 19 at 6:32 PM

$ATOS complete and utter shareholder destruction, yet people here still believe.. why? Rare disease trials are at least 3 years out. They are going to dilute and raise cash by year end. Why not sell now and get out? Also could easily start a class action lawsuit but bulls are too dumb to figure out where to start.

0 · Reply

NOYES Sep. 19 at 12:19 AM

$ATOS these fkers wants to raise again.. Opportunistically raising capital wtf..

2 · Reply

ncdorc Sep. 18 at 11:46 PM

$ATOS Atossa had to delay the metastatic breast cancer IND due to funding constraints, I’m wondering whether expanding the pipeline into DMD/MAS makes sense, even with the potential PRV upside. Wouldn’t it be more prudent to focus the limited capital on the existing oncology programs first?

1 · Reply

ShowMeThaMonay Sep. 18 at 9:56 PM

$ATOS

1 · Reply

ShowMeThaMonay Sep. 18 at 9:29 PM

$ATOS terrible stock, sad board. Take me back to the good ole days 🙌🏻.

0 · Reply

NGCS Sep. 18 at 9:01 PM

$ATOS I feel sorry for you folks. I was also invested here, but I told you 12 months ago that I took all my money from ATOS (with loss and very sad) and took it all to TVGN (bought at 6,48 average) and PGY (I sold this with 50% profit a weeks ago). Sincerely I am still with global loss because of ATOS, but I think I could recover some money in TVGN (IMO it is supposed to get 20 - 50 usd in 1 - 6 months, say, x3 minimum). NFA, it is only my DD. Please do yours.

0 · Reply

ProfProfit Sep. 18 at 8:42 PM

$ATOS i give up

0 · Reply

Warrens__Buffet_ Sep. 18 at 8:03 PM

$ATOS I’m thinking this gets back to under $1 by year end, then they start the new year with a fresh split destroying bulls even more 😂😂

0 · Reply

Warrens__Buffet_ Sep. 18 at 8:01 PM

$ATOS why has there been no class action lawsuit started by long term bagholding bulls here?

0 · Reply

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Aug 7, 2026, 7:00 AM EDT - 6 weeks ago

Atossa Therapeutics Quarterly report: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 6 weeks ago

Atossa Therapeutics Earnings release: Q2 2026

Jul 28, 2026, 8:30 AM EDT - 7 weeks ago

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Jul 21, 2026, 8:30 AM EDT - 2 months ago

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Jun 12, 2026, 5:30 PM EDT - 3 months ago

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Jun 11, 2026, 8:00 AM EDT - 3 months ago

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

May 27, 2026, 8:30 AM EDT - 3 months ago

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

May 20, 2026, 4:45 PM EDT - 4 months ago

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

May 19, 2026, 4:00 PM EDT - 4 months ago

Atossa Therapeutics Transcript: Status update

May 14, 2026, 8:30 AM EDT - 4 months ago

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

May 8, 2026, 8:45 AM EDT - 4 months ago

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 8, 2026, 7:00 AM EDT - 4 months ago

Atossa Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 4 months ago

Atossa Therapeutics Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 months ago

Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

May 4, 2026, 8:30 AM EDT - 4 months ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Proxy statement: Proxy filing

Mar 25, 2026, 5:30 PM EDT - 5 months ago

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Mar 25, 2026, 7:00 AM EDT - 5 months ago

Atossa Therapeutics Earnings release: Q4 2025

Mar 25, 2026, 7:00 AM EDT - 5 months ago

Atossa Therapeutics Annual report: Q4 2025

Mar 20, 2026, 8:00 AM EDT - 6 months ago

Atossa Therapeutics Proxy statement: Proxy filing

Mar 19, 2026, 8:00 AM EDT - 6 months ago

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Mar 12, 2026, 8:00 AM EDT - 6 months ago

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Feb 11, 2026, 8:30 AM EST - 7 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Feb 11, 2026, 6:00 AM EST - 7 months ago

Atossa Therapeutics Slides: Corporate presentation

Feb 5, 2026, 8:30 AM EST - 7 months ago

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Jan 21, 2026, 9:05 AM EST - 8 months ago

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025

Jan 16, 2026, 4:40 PM EST - 8 months ago

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

Jan 6, 2026, 8:15 AM EST - 8 months ago

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Dec 22, 2025, 7:00 AM EST - 9 months ago

Atossa Therapeutics Proxy statement: Proxy Filing

Dec 17, 2025, 8:15 AM EST - 9 months ago

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Dec 15, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

Dec 12, 2025, 7:00 AM EST - 9 months ago

Atossa Therapeutics Proxy statement: Proxy Filing

Dec 11, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Dec 9, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

Dec 4, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Dec 2, 2025, 8:00 AM EST - 9 months ago

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Nov 17, 2025, 9:07 AM EST - 10 months ago

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Nov 12, 2025, 8:30 AM EST - 10 months ago

Atossa Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

Atossa Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:15 AM EST - 10 months ago

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 6, 2025, 8:00 AM EST - 10 months ago

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Oct 21, 2025, 8:00 AM EDT - 11 months ago

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Oct 15, 2025, 8:00 AM EDT - 11 months ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Oct 13, 2025, 8:00 AM EDT - 11 months ago

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Oct 1, 2025, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 3:00 PM EDT - 1 year ago

Atossa Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q2 2025

Jul 29, 2025, 7:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 5, 2025, 8:10 AM EDT - 1 year ago

Atossa Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 4:15 PM EDT - 1 year ago

Atossa Therapeutics Transcript: Status Update

May 20, 2025, 9:00 AM EDT - 1 year ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

May 12, 2025, 6:00 PM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Atossa Therapeutics Quarterly report: Q1 2025

Apr 30, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Proxy statement: Proxy Filing

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings Call Transcript: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Annual report: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Slides: Q4 2024

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 1 year ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Bunster Sep. 20 at 1:51 AM

0 · Reply

Warrens__Buffet_ Sep. 19 at 6:32 PM

0 · Reply

NOYES Sep. 19 at 12:19 AM

$ATOS these fkers wants to raise again.. Opportunistically raising capital wtf..

2 · Reply

ncdorc Sep. 18 at 11:46 PM

1 · Reply

ShowMeThaMonay Sep. 18 at 9:56 PM

$ATOS

1 · Reply

ShowMeThaMonay Sep. 18 at 9:29 PM

$ATOS terrible stock, sad board. Take me back to the good ole days 🙌🏻.

0 · Reply

NGCS Sep. 18 at 9:01 PM

0 · Reply

ProfProfit Sep. 18 at 8:42 PM

$ATOS i give up

0 · Reply

Warrens__Buffet_ Sep. 18 at 8:03 PM

$ATOS I’m thinking this gets back to under $1 by year end, then they start the new year with a fresh split destroying bulls even more 😂😂

0 · Reply

Warrens__Buffet_ Sep. 18 at 8:01 PM

$ATOS why has there been no class action lawsuit started by long term bagholding bulls here?

0 · Reply

uNsUsPeCtNoT Sep. 18 at 5:42 PM

$ATOS watch your wallet when goes to his island vacation. It’s getting close.

0 · Reply

Michaeljin_101 Sep. 18 at 2:20 PM

$ATOS 掉了掉了，掉了个鸡巴。

0 · Reply

ncdorc Sep. 18 at 8:10 AM

$ATOS Hmm… I know Atossa said the I-SPY 2 data is expected to be available in the second half of 2026, but did they actually say that they would release the data during H2?

1 · Reply

amsterplus Sep. 17 at 10:21 PM

$ATOS Atossa's BoD abd Quay have certainly screwed investors royally. I hope they enjoyed cheating, lying (tis' the year for Atossa), essentially robbing investors and being outright maggots -info from Atossa has always been scarce but lately almost disappeared. Should have known it was fluff when Quay himself would not invest. Additionally, PR managers and CFOs appeared to be playing musical chairs. If a lawsuit is being considered, those would be the people that have the inside information.

2 · Reply

The_Real_Heisenberg Sep. 17 at 5:59 PM

$ATOS "Nows the time to get in" - Quay, when ATOS was 5x the price.

1 · Reply

dcajic2 Sep. 17 at 5:44 PM

$ATOS how is there over 63k watchers? Stock is down. They haven’t even begun bigger phase 2 study: it looks likely any data has been moved into 2027.

1 · Reply

Warrens__Buffet_ Sep. 17 at 2:19 PM

$ATOS bulls here should really organize for a class action lawsuit. I just read about a few other stocks that had one and shareholders walked away with a decent chunk. Surprised nothing has happened here yet.. you guys just not care enough 😂😂 this is going down much more

0 · Reply

NOYES Sep. 17 at 10:39 AM

$ATOS on recent filing they report Quay 's external engagements but it was happening in the past as well..failure to reporting?? Do we have a case against these bastards??

0 · Reply

NOYES Sep. 17 at 9:50 AM

$ATOS elevated investment risk tag by rhood

0 · Reply

Warrens__Buffet_ Sep. 16 at 3:37 PM

$ATOS I see that idiot bunster is still 😂😂

1 · Reply

Warrens__Buffet_ Sep. 15 at 4:43 PM

$ATOS remember me? I was right all along about this POS.

1 · Reply

dcajic2 Sep. 15 at 1:54 PM

$ATOS can we say the end is near? Even the bulls have left the building.

0 · Reply

Market Cap	22.15M
Revenue (ttm)	0.00
Net Income (ttm)	-34.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	39,700
Avg Vol	59,962
Day's Range	N/A - N/A
Shares Out	9.98M
Stochastic %K	0%
Beta	1.27
Analysts	Strong Sell
Price Target	$17.00